Since germline BRCA2 mutations are associated with a five-to-eight increase in the risk of developing prostate cancers, which are more aggressive and with a shorter survival rate, male carriers should begin prostate screening at age 45. The gene discussed is BRCA2; the disease is prostate cancer.